extracellular exosome
Overview
Extracellular exosomes are small extracellular vesicles released by cells into the extracellular space and found in many body fluids, including human plasma, urine, and nipple discharge. They carry membrane proteins, lipids, and nucleic acids that reflect the molecular state of their parent cells, making them important mediators of intercellular communication and attractive candidates for biomarker discovery, drug delivery, and therapeutic engineering. In biomedical research, exosomes are often discussed together with broader extracellular vesicle populations, but the term specifically refers to a nanoscale vesicular subtype with a defined biogenesis pathway.
From a therapeutic and translational perspective, exosomes are being investigated both as natural delivery vehicles and as disease-associated analytes. Their membrane composition and cargo can be exploited for targeted delivery of drugs, nucleic acids, or genome-editing systems, while their endogenous origin may offer advantages over synthetic carriers. At the same time, their abundance and molecular signatures are being studied for noninvasive sensing strategies in cancer and other diseases, including breast cancer, bladder cancer, and neurological and inflammatory disorders.
Recent Publications Summary
Recent studies used extracellular exosomes as both therapeutic vehicles and disease biomarkers across cancer, cardiovascular disease, infection, and inflammatory models. In a TMUV infection model, exosomes derived from infected cells carried viral genomic RNA and multiple viral proteins, entered HEK293 cells through dynamin-dependent, cholesterol-sensitive caveolae-mediated endocytosis, and promoted productive infection by suppressing antiviral immune gene expression; this process was linked to an NS4A–Rab27a regulatory axis that enhanced exosome release 42572027Aug. In cardiac injury, M2 macrophage-derived exosomes containing miR-124 attenuated Ang II-induced hypertrophy and fibrosis in mice and reduced fibrotic and hypertrophic responses in cardiac cells, with Calpain-1 identified as a key downstream target 42102612May. In Sandhoff disease, inflammatory-primed stromal cell extracellular vesicles reduced in vitro neuroinflammation and lowered IL-6, TNF-α, and IL-1β in neuronal-mixed glia 42436308Jul. In rheumatoid arthritis, USP21-enriched mesenchymal stem cell-derived exosomes alleviated synovial hyperplasia, oxidative stress, and joint damage in a collagen-induced arthritis model by restoring autophagy balance in fibroblast-like synoviocytes 42302977Jun.
Several publications focused on exosome characterization and liquid biopsy applications. A smartphone-based fluorescence biosensing platform detected CD63-positive exosomes with a CD63-specific aptamer capture step and a tumor-specific fluorescent aptamer, achieving detection within 45 minutes and a reported limit of detection of 4.58 × 10^6 particles/ml 42520835Jul. A peptide-based fluorescent probe platform was developed for HER2-positive exosomes, using optimized HER2-binding peptides and multivariate fluorescence analysis to distinguish HER2-enriched exosomes in cell-derived samples, plasma, and urine 42215863May. In bladder cancer, a herringbone microfluidic system with photonic crystal-encoded hydrogel microcarriers enabled exosome enrichment and multiplexed profiling of six proteomic biomarkers from urinary exosomes, supporting high-throughput early detection and monitoring 41740420Feb. Exosomal microRNA analysis was also explored in nipple discharge for breast cancer screening, with cellulose nanofiber sheets proposed to facilitate biomarker identification from low-volume samples 42307695Jun.
Other studies examined how exosome properties vary with physiological state and tissue source. In healthy dogs, aging was associated with lower plasma exosome yield and altered size characteristics, alongside differences in molecular cargo including selected miRNAs 42319614Jun. In postoperative intra-abdominal adhesion, mesenchymal stem cell-derived exosomes from umbilical cord and adipose tissue were compared in a rat model, with treatment groups assessed for adhesion severity, fibrosis, inflammation, neovascularization, and markers such as collagen I, FGF2, VEGF, and HIF-1α 41997426Apr. In breast cancer cell models, menstrual blood stem cell-derived exosomes reduced cell survival, migration, and angiogenesis-related behavior in MDA-MB-231 and SK-BR-3 cells, with associated changes in apoptosis, ROS generation, and expression of BAX, BCL-2, MMP-2, and VEGF 42159846May. Reviews of diabetic kidney disease also highlighted mesenchymal stem cells and their derived extracellular vesicles as regenerative approaches being investigated alongside senotherapeutics 41581730Jan, while broader CRISPR-Cas12a diagnostics reviews noted exosomes among the analytes targeted by emerging biosensing technologies 41500123Jan.
What Changes, What Holds
1. Exosomes now appear to carry pathogenic viral material and can amplify infection
NEW DIRECTION Exosomes from infected cells are no longer just intercellular messengers or candidate delivery vehicles; in this model they also shuttle viral RNA and proteins into new cells and help suppress antiviral responses, while an NS4A–Rab27a axis increases their release 42572027Aug. That adds a disease-propagating role not covered by the baseline and tempers any blanket therapeutic optimism. The host-derived cardiac, neuroinflammatory, and arthritis studies still fit the broader therapeutic use of exosomes 42102612May42436308Jul.
2. Exosome analysis is moving toward faster, more selective liquid-biopsy workflows
METHOD Smartphone fluorescence readout, peptide-targeted probes, microfluidic enrichment, and low-volume nipple-discharge processing change how exosomes are captured and profiled rather than what exosomes are understood to do 42520835Jul42215863May. The baseline already frames them as biomarker candidates, and these studies mainly sharpen that translational promise by making detection more practical, multiplexed, and sample-sparing. The underlying biomarker concept is reinforced, but the new contribution is methodological rather than conceptual.
3. Exosome properties are increasingly treated as state-dependent and source-dependent
REINFORCES Aging-related shifts in plasma yield and cargo, comparisons across mesenchymal stem cell sources, and context-specific anti-inflammatory or anti-tumor effects all support the baseline view that exosome composition reflects the parent cell and physiological state 42319614Jun41997426Apr. Rather than changing what exosomes are for, this work sharpens the importance of source, age, and disease context when interpreting them as analytes or therapeutics. It also argues against treating all exosome preparations as interchangeable.
Overview update candidates: infection-enhancing exosomal viral cargo; state- and source-dependence of exosome yield and cargo.
extracellular exosome
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding extracellular exosome are described as follows:
- intercellular communication (Biological Process) — 4 papers: PMIDs 42572027, 42520835, 42485583, 42473083
- cellular senescence (Biological Process) — 3 papers: PMIDs 42440223, 42319614, 41581730
- diabetic nephropathy (Disease) — 3 papers: PMIDs 42440223, 41951011, 41581730
- inflammation (Biological Process) — 3 papers: PMIDs 42119497, 41951011, 41915968
- oxidative stress (Biological Process) — 3 papers: PMIDs 42469965, 41967722, 41915968
- Alzheimer's disease (Disease) — 2 papers: PMIDs 42475384, 41812941
- breast cancer (Disease) — 2 papers: PMIDs 42159846, 42055255
- chronic inflammation (Disease) — 2 papers: PMIDs 41967722, 41581730
- CRISPR-Cas12a (Technology) — 2 papers: PMIDs 41833894, 41500123
- M2 macrophage (Cellular Component) — 2 papers: PMIDs 42530712, 42102612
- protein (Protein) — 2 papers: PMIDs 42485583, 42473083
- tumor microenvironment (Biological Process) — 2 papers: PMIDs 42055255, 41500123
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study extracellular exosome:
- western blot (Technology) — 7 papers: PMIDs 42461467, 42345093, 42310140, 42159846, etc.
- flow cytometry (Technology) — 6 papers: PMIDs 42530712, 42472813, 42345093, 42159846, etc.
- nanoparticle tracking analysis (Technology) — 6 papers: PMIDs 42461467, 42319614, 42310140, 42119839, etc.
- liposome (Other) — 4 papers: PMIDs 42485583, 42429747, 42357492, 42134708
- transmission electron microscopy (Technology) — 4 papers: PMIDs 42461467, 42159846, 42119839, 42102612
- ELISA (Technology) — 3 papers: PMIDs 42461467, 42159846, 42107690
- endothelial cell (Cellular Component) — 3 papers: PMIDs 42560582, 42107690, 41915968
- mesenchymal stem cell (Cellular Component) — 3 papers: PMIDs 42436308, 42262433, 42119497
- mouse (Organism) — 3 papers: PMIDs 42567345, 42134712, 42119839
- xenograft (Organism) — 3 papers: PMIDs 42560582, 42530712, 42120691
- bone marrow mesenchymal stem cell (Cellular Component) — 2 papers: PMIDs 42390648, 41839285
- bronchoalveolar lavage fluid (Other) — 2 papers: PMIDs 42473083, 41713945
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to extracellular exosome include:
- microRNA (Other) — 3 papers: PMIDs 42319614, 42307695, 42214224
- PI3K/Akt signaling pathway (Pathway) — 2 papers: PMIDs 42461467, 42119839
- AcrVA1 (Protein) — 1 paper: PMIDs 42096138
- adenosine (Chemical) — 1 paper: PMIDs 42324646
- Alpha-fetoprotein (AFP) (Protein) — 1 paper: PMIDs 42190059
- angiogenesis (Biological Process) — 1 paper: PMIDs 42159846
- Apolipoprotein E4 (APOE4) (Protein) — 1 paper: PMIDs 41812941
- apoptotic process (Biological Process) — 1 paper: PMIDs 42159846
- ATP-binding cassette sub-family B member 1 (ABCB1) (Protein) — 1 paper: PMIDs 42235483
- basic fibroblast growth factor (Protein) — 1 paper: PMIDs 42461467
- BCL2 apoptosis regulator (Protein) — 1 paper: PMIDs 42033944
- blood–brain barrier (Biological Process) — 1 paper: PMIDs 42472813
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with extracellular exosome include:
- Migration (Biological Process) — 7 papers: PMIDs 42560582, 42530712, 42455592, 42159846, etc.
- apoptotic process (Biological Process) — 6 papers: PMIDs 42530712, 42469965, 42345093, 42159846, etc.
- collagen deposition (Clinical Metric) — 4 papers: PMIDs 42567345, 42461467, 42402577, 42119497
- oxidative stress (Biological Process) — 4 papers: PMIDs 42381381, 42302977, 42134712, 41967722
- Proliferation (Biological Process) — 4 papers: PMIDs 42530712, 42120691, 42119839, 42119497
- angiogenesis (Biological Process) — 3 papers: PMIDs 42560582, 42469965, 42119497
- inflammation (Biological Process) — 3 papers: PMIDs 42469965, 42119497, 41997426
- M2 phenotype (Biological Process) — 3 papers: PMIDs 42469965, 42134712, 42055255
- proinflammatory cytokine (Biological Process) — 3 papers: PMIDs 42436308, 42390648, 41967722
- transforming growth factor (Clinical Metric) — 3 papers: PMIDs 42530712, 42455592, 42120691
- wound closure (Clinical Metric) — 3 papers: PMIDs 42402577, 42262433, 42119839
- Arginase 1 (ARG1) (Protein) — 2 papers: PMIDs 42436308, 42134712
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding extracellular exosome are summarized below:
- breast cancer (Disease) — 2 papers: PMIDs 42159846, 42055255
- immune dysregulation (Biological Process) — 2 papers: PMIDs 42061206, 41967722
- inflammation (Biological Process) — 2 papers: PMIDs 42134712, 42119497
- Migration (Biological Process) — 2 papers: PMIDs 42159846, 42055255
- nonhormonal, and nonsurgical therapeutic strategy (Other) — 2 papers: PMIDs 42461467, 42390648
- oxidative stress (Biological Process) — 2 papers: PMIDs 42469965, 41967722
- acute lung injury (Disease) — 1 paper: PMIDs 42134712
- acute myeloid leukemia (Disease) — 1 paper: PMIDs 42560582
- ADO-driven immune suppression (Other) — 1 paper: PMIDs 42324646
- age-related disorders (Other) — 1 paper: PMIDs 42319614
- angiogenesis (Biological Process) — 1 paper: PMIDs 42119497
- Anti-adhesive effect (Biological Process) — 1 paper: PMIDs 41997426